Intra-venous bevacizumab in hereditary hemorrhagic telangiectasia (HHT): A retrospective study of 46 patients.

ABSTRACT:

Background

Bevacizumab, an anti-VEGF monoclonal antibody, has recently emerged as a new option for severe forms of hereditary hemorrhagic telangiectasia (HHT). Its utilization in this orphan disease has rapidly spread despite the lack of randomized trials and international guidelines. The objective of this study is to report the main clinical data (baseline characteristics, dose schedule, efficacy, adverse events and deaths) of HHT patients treated by intravenous bevacizumab in France.

Methods

Retrospective observational study of HHT patients treated with bevacizumab for a severe form of the disease in the 14 centers of the French HHT network.

Results

Forty-six patients (median age: 68 years) were treated between March 2009 and May 2015. Ten patients were treated for

SUBMITTER: Guilhem A 

PROVIDER: S-EPMC5708634 | biostudies-literature | 2017

REPOSITORIES: biostudies-literature